The table below shows CytomX Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$25.55M
-$21.04M
-$26.05M
$9.35M
-$41.31M
-$29.94M
Capital expenditure
$0.00
$119.00K
$115.00K
$48.00K
$736.00K
$982.00K
Investing cash flow
-$192.78M
$30.60M
$44.88M
-$146.64M
-$736.00K
$59.01M
Dividends paid
-
-
-
-
CTMX operating cash flow (10-K history)
CytomX Therapeutics, Inc. reported operating cash flow of -$75.59M for fiscal year 2025. That is up 12.3% from -$86.23M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.03M (FY 2016) to -$75.59M. Figures come from the company's audited annual reports as filed with the SEC.